PharmaResearch Co., Ltd. (214450.KQ)
KRW 259500.0
(2.77%)
KRW 259500.0
(2.77%)
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2023 | 100.81 Billion KRW | 39.96% |
| 2022 | 65.91 Billion KRW | 25.58% |
| 2021 | 52.48 Billion KRW | 57.03% |
| 2020 | 33.42 Billion KRW | 75.35% |
| 2019 | 19.06 Billion KRW | 130.05% |
| 2018 | 8.28 Billion KRW | -43.87% |
| 2017 | 14.76 Billion KRW | 4.65% |
| 2016 | 14.1 Billion KRW | -12.36% |
| 2015 | 16.09 Billion KRW | 0.0% |
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2024 Q2 | 30.76 Billion KRW | 23.35% |
| 2024 Q1 | 26.66 Billion KRW | 30.88% |
| 2023 Q4 | 20.37 Billion KRW | -25.89% |
| 2023 Q2 | 23.64 Billion KRW | 14.02% |
| 2023 Q1 | 20.73 Billion KRW | 23.66% |
| 2023 Q3 | 27.49 Billion KRW | 16.27% |
| 2023 FY | 92.25 Billion KRW | 39.96% |
| 2022 Q1 | 15.23 Billion KRW | 20.59% |
| 2022 FY | 65.91 Billion KRW | 25.58% |
| 2022 Q4 | 16.77 Billion KRW | 1.53% |
| 2022 Q2 | 17.39 Billion KRW | 14.16% |
| 2022 Q3 | 16.51 Billion KRW | -5.02% |
| 2021 Q1 | 12.29 Billion KRW | 8.33% |
| 2021 Q2 | 13.91 Billion KRW | 13.18% |
| 2021 Q3 | 13.65 Billion KRW | -1.88% |
| 2021 Q4 | 12.63 Billion KRW | -7.46% |
| 2021 FY | 52.48 Billion KRW | 57.03% |
| 2020 Q2 | 8.04 Billion KRW | 76.87% |
| 2020 Q3 | 9.47 Billion KRW | 17.78% |
| 2020 Q4 | 11.34 Billion KRW | 19.7% |
| 2020 FY | 33.42 Billion KRW | 75.35% |
| 2020 Q1 | 4.55 Billion KRW | -28.71% |
| 2019 Q2 | 4.14 Billion KRW | -15.52% |
| 2019 FY | 19.06 Billion KRW | 130.05% |
| 2019 Q4 | 6.38 Billion KRW | 76.04% |
| 2019 Q3 | 3.62 Billion KRW | -12.54% |
| 2019 Q1 | 4.9 Billion KRW | 402.72% |
| 2018 FY | 8.28 Billion KRW | -43.87% |
| 2018 Q4 | 976.19 Million KRW | -29.46% |
| 2018 Q3 | 1.38 Billion KRW | -23.03% |
| 2018 Q1 | 4.54 Billion KRW | 15554.24% |
| 2018 Q2 | 1.79 Billion KRW | -60.46% |
| 2017 Q3 | 5.82 Billion KRW | 52.16% |
| 2017 Q2 | 3.82 Billion KRW | -26.8% |
| 2017 Q1 | 5.22 Billion KRW | 222.37% |
| 2017 FY | 14.76 Billion KRW | 4.65% |
| 2017 Q4 | -29.42 Million KRW | -100.51% |
| 2016 Q4 | 1.62 Billion KRW | -65.57% |
| 2016 Q1 | 3.63 Billion KRW | -13.74% |
| 2016 FY | 14.1 Billion KRW | -12.36% |
| 2016 Q3 | 4.7 Billion KRW | 13.75% |
| 2016 Q2 | 4.13 Billion KRW | 13.86% |
| 2015 FY | 16.09 Billion KRW | 0.0% |
| 2015 Q4 | 4.21 Billion KRW | -13.33% |
| 2015 Q3 | 4.86 Billion KRW | 0.0% |
| Name | Operating Income | Operating Income Difference |
|---|---|---|
| HLB Co., Ltd. | -125.02 Billion KRW | 180.638% |
| iNtRON Biotechnology, Inc. | -3.28 Billion KRW | 3169.059% |
| BINEX Co., Ltd. | 1.04 Billion KRW | -9572.925% |
| Bioneer Corporation | 791.75 Million KRW | -12633.436% |
| Anterogen.Co.,Ltd. | -5.07 Billion KRW | 2087.002% |
| MEDIPOST Co., Ltd. | -25.13 Billion KRW | 501.172% |
| CrystalGenomics, Inc. | -30.91 Billion KRW | 426.133% |
| Helixmith Co., Ltd | -35.24 Billion KRW | 386.044% |
| Chabiotech Co.,Ltd. | -9.42 Billion KRW | 1169.658% |
| Medy-Tox Inc. | 17.32 Billion KRW | -482.008% |
| Peptron, Inc. | -15.6 Billion KRW | 746.144% |
| Amicogen, Inc. | 2.05 Billion KRW | -4803.231% |
| Genexine, Inc. | -41.24 Billion KRW | 344.46% |
| HLB Therapeutics Co.,Ltd. | -8.7 Billion KRW | 1258.785% |
| LegoChem Biosciences, Inc. | -80.82 Billion KRW | 224.739% |
| ALTEOGEN Inc. | -9.73 Billion KRW | 1135.422% |
| SillaJen, Inc. | -21.34 Billion KRW | 572.304% |
| JETEMA, Co., Ltd. | 2.63 Billion KRW | -3728.062% |
| OliX Pharmaceuticals,Inc | -18.18 Billion KRW | 654.388% |
| Genomictree Inc. | -17.3 Billion KRW | 682.642% |
| MedPacto, Inc. | -28.75 Billion KRW | 450.644% |
| D&D Pharmatech | -13.48 Billion KRW | 847.556% |
| EASY BIO,Inc. | 20.63 Billion KRW | -388.664% |
| GI Innovation, Inc. | -55.6 Billion KRW | 281.314% |